Sandoz Faces US Denosumab Lawsuit Ahead Of Key 2025 Patent Expiry
Sandoz’s BLA Accepted For FDA Review In February; Denosumab Sales In Billions
Months after announcing that its GP2411 biosimilar denosumab candidate was accepted for filing by the FDA, Sandoz has been sued for alleged patent infringement by originator Amgen.
